These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30039694)
1. Fatal asthma after omalizumab and controller therapy discontinuation. Lombardi C; Cottini M; Passalacqua G Eur Ann Allergy Clin Immunol; 2018 Jul; 50(5):235-236. PubMed ID: 30039694 [No Abstract] [Full Text] [Related]
2. Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports. Gomes N; Miranda J; Lopes S; Carneiro-Leão L; Torres Costa J; Baudrier T; Azevedo F J Investig Allergol Clin Immunol; 2020; 30(3):191-192. PubMed ID: 31820738 [No Abstract] [Full Text] [Related]
3. Occupational allergic respiratory disease (rinoconjunctivitis and asthma) in a cheese factory worker. Gómez Torrijos E; García Rodriguez C; Veleiro Pérez B; Bartolomé B; Prado Barragan M; Garcia Rodriguez R J Allergy Clin Immunol Pract; 2018; 6(4):1416-1417. PubMed ID: 29342450 [No Abstract] [Full Text] [Related]
4. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab. Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192 [TBL] [Abstract][Full Text] [Related]
5. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846 [TBL] [Abstract][Full Text] [Related]
6. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319 [TBL] [Abstract][Full Text] [Related]
7. Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies. Wright LS; Phipatanakul W Ann Allergy Asthma Immunol; 2016 Jul; 117(1):17-20. PubMed ID: 27371967 [No Abstract] [Full Text] [Related]
8. Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. Hoch HE; Calatroni A; West JB; Liu AH; Gergen PJ; Gruchalla RS; Khurana Hershey GK; Kercsmar CM; Kim H; Lamm CI; Makhija MM; Mitchell HE; Teach SJ; Wildfire JJ; Busse WW; Szefler SJ J Allergy Clin Immunol; 2017 Oct; 140(4):1130-1137.e5. PubMed ID: 28238748 [TBL] [Abstract][Full Text] [Related]
9. The use of anti-IgE therapy beyond allergic asthma. Stokes JR; Casale TB J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342 [TBL] [Abstract][Full Text] [Related]
10. Atopic dermatitis is an important comorbidity in severe asthma. Lee JK; Han D Ann Allergy Asthma Immunol; 2018 Jun; 120(6):661-662. PubMed ID: 29496463 [No Abstract] [Full Text] [Related]
11. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases. Aydın Ö; Sözener ZÇ; Soyyiğit Ş; Kendirlinan R; Gençtürk Z; Mısırlıgil Z; Mungan D; Sin BA; Demirel YS; Çelik GE; Bavbek S Allergy Asthma Proc; 2015; 36(6):493-500. PubMed ID: 26534756 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis. Christensen MJ; Bindslev-Jensen C J Allergy Clin Immunol Pract; 2017; 5(1):204-206. PubMed ID: 27839749 [No Abstract] [Full Text] [Related]
14. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879 [TBL] [Abstract][Full Text] [Related]
15. Clinical option of omalizumab on refractory vasospastic angina with asthma and eosinophilic chronic rhinosinusitis. Hamada S; Tatsumi S; Taniguchi T; Yasuba H J Allergy Clin Immunol Pract; 2016; 4(4):753-5. PubMed ID: 27017534 [No Abstract] [Full Text] [Related]